NO20021476L - Farmasöytisk b¶rerformulering - Google Patents

Farmasöytisk b¶rerformulering

Info

Publication number
NO20021476L
NO20021476L NO20021476A NO20021476A NO20021476L NO 20021476 L NO20021476 L NO 20021476L NO 20021476 A NO20021476 A NO 20021476A NO 20021476 A NO20021476 A NO 20021476A NO 20021476 L NO20021476 L NO 20021476L
Authority
NO
Norway
Prior art keywords
pharmaceutical
borer
formulation
fatty acid
acid esters
Prior art date
Application number
NO20021476A
Other languages
English (en)
Other versions
NO20021476D0 (no
Inventor
Joseph Kyuwung Yoon
Richard William Saunders
Mahdi Bakir Fawzi
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20021476D0 publication Critical patent/NO20021476D0/no
Publication of NO20021476L publication Critical patent/NO20021476L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet bærersystemer nyttige for fremstilling av farmasøytiske formuleringer, idet systemene omfatter, i vektprosentandeler, fra omtrent 1 % til omtrent 20 %, fortrinnsvis fra omtrent 5 % til omtrent 12 %, av en overflateaktive middelkomponent; fra omtrent 55 % til omtrent 93 %, fortrinnsvis fra omtrent 60 % til omtrent 85, av en komponent av en eller flere polyetylenglkoler (PEG); og fra omtrent 1 % til omtrent 25 %, fortrinnsvis fra omtrent 5 % til omtrent 15 %, av "en eller flere sukrosefettsyrestere eller polybinylpyrrolidon (PVP) med en K.-verdi på mellom omtrent 15 og omtrent 90, fortrinnsvis med en K-verdi på fra omtrent 16 til omtrent 18, mest foretrukket omtrent 17, som definert i USP/NF, eller en kombina- jon av en eller flere sukrosefettsyreestere eller PVP, og eventuelt en eller flere farmasøytisk akseptable konserveringsmidler, slik som BHA, BHT, askorbyl- palmitat eller benzylalkohol.
NO20021476A 1999-09-27 2002-03-25 Farmasöytisk b¶rerformulering NO20021476L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40616499A 1999-09-27 1999-09-27
PCT/US2000/026381 WO2001022942A1 (en) 1999-09-27 2000-09-26 Pharmaceutical carrier formulation

Publications (2)

Publication Number Publication Date
NO20021476D0 NO20021476D0 (no) 2002-03-25
NO20021476L true NO20021476L (no) 2002-04-16

Family

ID=23606801

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021476A NO20021476L (no) 1999-09-27 2002-03-25 Farmasöytisk b¶rerformulering

Country Status (18)

Country Link
EP (1) EP1216029A1 (no)
JP (1) JP2003510267A (no)
KR (1) KR20020064289A (no)
CN (1) CN1399542A (no)
AR (1) AR025867A1 (no)
AU (1) AU7716100A (no)
BR (1) BR0014308A (no)
CA (1) CA2388471A1 (no)
CZ (1) CZ20021082A3 (no)
EA (1) EA200200415A1 (no)
HK (1) HK1044485A1 (no)
HU (1) HUP0202652A3 (no)
IL (1) IL148543A0 (no)
MX (1) MXPA02003190A (no)
NO (1) NO20021476L (no)
PL (1) PL354331A1 (no)
WO (1) WO2001022942A1 (no)
ZA (1) ZA200203311B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
JPWO2004073692A1 (ja) * 2003-02-18 2006-06-01 山下　伸二 難水溶性薬物のハードカプセル剤
CN100342856C (zh) * 2003-04-10 2007-10-17 上海医药工业研究院 达那唑半固体骨架制剂的组合物
EP1959935A2 (en) * 2005-10-26 2008-08-27 Banner Pharmacaps Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
BRPI0718042A2 (pt) * 2006-10-31 2013-11-12 Wyeth Corp Formulações semissólidas de inibidores de enzima fosfolipase
ES2944116T3 (es) * 2017-12-20 2023-06-19 Firmenich & Cie Composiciones para el cuidado bucal
EP3733826B1 (en) * 2019-05-03 2024-07-17 The Procter & Gamble Company Particle treatment compositions comprising an antioxidant
JP2025519627A (ja) * 2022-06-13 2025-06-26 アール．ピー．シェーラー テクノロジーズ，エルエルシー 腸溶性ビサコジルソフトジェルカプセル

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
AR025867A1 (es) 2002-12-18
IL148543A0 (en) 2002-09-12
ZA200203311B (en) 2003-12-31
WO2001022942A1 (en) 2001-04-05
CA2388471A1 (en) 2001-04-05
CZ20021082A3 (cs) 2002-06-12
MXPA02003190A (es) 2002-09-30
JP2003510267A (ja) 2003-03-18
CN1399542A (zh) 2003-02-26
BR0014308A (pt) 2002-05-21
HK1044485A1 (zh) 2002-10-25
HUP0202652A2 (hu) 2004-05-28
HUP0202652A3 (en) 2004-06-28
NO20021476D0 (no) 2002-03-25
EA200200415A1 (ru) 2002-10-31
KR20020064289A (ko) 2002-08-07
AU7716100A (en) 2001-04-30
EP1216029A1 (en) 2002-06-26
PL354331A1 (en) 2004-01-12

Similar Documents

Publication Publication Date Title
US6946120B2 (en) Pharmaceutical composition
CA2282513A1 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
IE871335L (en) Steroid formulations.
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
EP0215423A3 (en) Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation
RU2003132426A (ru) Фармацевтический раствор арипипразола для орального применения
WO1998020872B1 (en) Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections
NO20021476L (no) Farmasöytisk b¶rerformulering
CA2337745A1 (en) Human growth hormone aqueous formulation
PT918507E (pt) Formulacoes em aerossol
CA2471041A1 (en) Compositions and methods for enhancing corticosteriod delivery
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
MX9204382A (es) Composiciones
EP1886691A3 (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
UA50807C2 (uk) Німесулідна гелева система для місцевого застосування і спосіб її отримання (варіанти)
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
CA2216277A1 (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
AR012868A1 (es) COMPOSICIoN FARMACÉUTICA QUE COMPRENDE UN PÉPTIDO AGONISTA DE LHRH, UN ANTAGONISTA DE LHRH O UN PÉPTIDO DE GRF Y NICOTINAMIDA.
WO2021216450A8 (en) Opioid antagonist formulations
WO2001022969A3 (en) Vasopressin agonist formulation and process
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification
NO20021475L (no) Vasopressinantagonist, formulering og fremgangsmåte
MX2023015458A (es) Formulacion de base lipidica que incrementa la penetracion al globo ocular de antibioticos de uso topico oftalmico.
CA2202520A1 (en) Lyophilized pharmaceutical preparations capable of providing aqueous drug composition having property of reversible thermosetting gelation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application